Glenmark moves closer to HIV drug launch

09 Nov 2010 Evaluate

Glenmark Pharmaceuticals has completed the third phase of human trials of Crofelemer, a new drug to treat HIV-related diarrhoea that could rake in over $80 million. The company has the right to launch the product in 140 countries, excluding the US, Europe, Japan and China, where its partners have marketing rights, Glenmark said in a statement. 

In the US and the Europe, Salix Pharmaceuticals has the rights to sell the drug while in Japan and China, Luye Pharmaceuticals has the rights to sell the product, which is the first of its type. Glenmark is the sole global supplier of its active pharmaceutical ingredient (API) to Salix Pharmaceuticals, except in China. Indian drugmakers have mastered developing low cost version of off-patent drugs and Crofelemer would be the country’s first new drug, if it is successfully launched. 

crackcrack

Glenmark Pharma Share Price

1622.40 -13.65 (-0.83%)
06-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1846.95
Dr. Reddys Lab 1350.65
Cipla 1490.55
Lupin 2357.75
Zydus Lifesciences 961.75
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.